The analysis showed that this advanced diagnostic test consistently identified more than 50% of hormone receptor positive early-stage breast cancer patients in AP countries as having low Recurrence
The application for approval of additional indication for type 2 diabetic incipient nephropathy for Micardis tablets was submitted by Nippon Boehringer Ingelheim on June 2006. The decision for
Celegene claimed that CITRE would bring together key parties from government, industry and academia. The collaboration’s main objective is to minimise the gap between basic scientific research and
Completing their strategic alliance in November 2008 to form the hybrid business model, Daiichi Sankyo and Ranbaxy have been moving forward to fully leverage the model. In addition
With this cooperation, Kemwell and Boehringer Ingelheim will provide customers with technology from Europe along with the benefit of low cost manufacturing from India. Process technology will originate
In May 2009 DSM and MCC already announced the signing of a memorandum of understanding for the intended swap. For both companies the businesses they will add to
Patients in both arms received standard of care treatment for severe sepsis in an intensive care unit (ICU) setting. As previously reported, the trial achieved its primary endpoint
AFFiRiS said that the specific reason for the ‘outing’ of project no 4 was the approval of public research promotion funds by the FFG. The vaccine is targeting
The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for
Earlier, in January 2010, Vion has filed a SPA with the FDA related to a randomised Phase II/III trial of Onrigin in combination with low-dose Ara-C (LDAC) in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.